These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 31633798)

  • 1. Association of PD-L1 expression status with the efficacy of PD-1/PD-L1 inhibitors and overall survival in solid tumours: A systematic review and meta-analysis.
    Liu X; Guo CY; Tou FF; Wen XM; Kuang YK; Zhu Q; Hu H
    Int J Cancer; 2020 Jul; 147(1):116-127. PubMed ID: 31633798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relative and absolute benefit of programmed death receptor-1 vs programmed death ligand 1 therapy in advanced non-small-cell lung cancer: A systematic review and meta-analysis.
    Yi K; Zhu Q; Kuang YK; Jiang SC; Hu H
    Int Immunopharmacol; 2020 Oct; 87():106852. PubMed ID: 32759049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis.
    Duan J; Cui L; Zhao X; Bai H; Cai S; Wang G; Zhao Z; Zhao J; Chen S; Song J; Qi C; Wang Q; Huang M; Zhang Y; Huang D; Bai Y; Sun F; Lee JJ; Wang Z; Wang J
    JAMA Oncol; 2020 Mar; 6(3):375-384. PubMed ID: 31876895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectivity and safety of PD-1/PD-L1 inhibitors for different level of PD-L1-positive, advanced NSCLC: A meta-analysis of 4939 patients from randomized controlled trials.
    Shi Y; Duan J; Guan Q; Xue P; Zheng Y
    Int Immunopharmacol; 2020 Jul; 84():106452. PubMed ID: 32339922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of PD-1/PD-L1 inhibitors in patients with advanced non-small cell lung cancer: A meta-analysis of randomized clinical trials.
    Peng TR; Wu TW
    Thorac Cancer; 2019 May; 10(5):1176-1181. PubMed ID: 30969033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis.
    Shen X; Zhao B
    BMJ; 2018 Sep; 362():k3529. PubMed ID: 30201790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis.
    Geng Y; Zhang Q; Feng S; Li C; Wang L; Zhao X; Yang Z; Li Z; Luo H; Liu R; Lu B; Wang X
    Cancer Med; 2021 Feb; 10(4):1222-1239. PubMed ID: 33465302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis.
    Mori K; Pradere B; Quhal F; Katayama S; Mostafaei H; Laukhtina E; Schuettfort VM; D'Andrea D; Egawa S; Bensalah K; Schmidinger M; Powles T; Shariat SF
    Cancer Treat Rev; 2021 Sep; 99():102242. PubMed ID: 34153830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive effect of PD-L1 expression for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatment for non-small cell lung cancer: A meta-analysis.
    Zhang B; Liu Y; Zhou S; Jiang H; Zhu K; Wang R
    Int Immunopharmacol; 2020 Mar; 80():106214. PubMed ID: 31982822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis.
    Elias R; Giobbie-Hurder A; McCleary NJ; Ott P; Hodi FS; Rahma O
    J Immunother Cancer; 2018 Apr; 6(1):26. PubMed ID: 29618381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Programmed Death-1/Programmed Death-Ligand 1-Axis Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Stratified by Human Papillomavirus Status: A Systematic Review and Meta-Analysis.
    Xu Y; Zhu G; Maroun CA; Wu IXY; Huang D; Seiwert TY; Liu Y; Mandal R; Zhang X
    Front Immunol; 2021; 12():645170. PubMed ID: 33897693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Checkpoint Inhibitors for Patients With Advanced Non-Small-Cell Lung Cancer: A Systematic Review.
    Ellis PM; Vella ET; Ung YC
    Clin Lung Cancer; 2017 Sep; 18(5):444-459.e1. PubMed ID: 28416123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of lactate dehydrogenase for melanoma patients receiving anti-PD-1/PD-L1 therapy: A meta-analysis.
    Xu J; Zhao J; Wang J; Sun C; Zhu X
    Medicine (Baltimore); 2021 Apr; 100(14):e25318. PubMed ID: 33832106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical benefits of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis.
    Rao Q; Li M; Xu W; Pang K; Guo X; Wang D; Liu J; Guo W; Zhang Z
    Hepatol Int; 2020 Sep; 14(5):765-775. PubMed ID: 32572818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship Between Progression-Free Survival, Objective Response Rate, and Overall Survival in Clinical Trials of PD-1/PD-L1 Immune Checkpoint Blockade: A Meta-Analysis.
    Ye J; Ji X; Dennis PA; Abdullah H; Mukhopadhyay P
    Clin Pharmacol Ther; 2020 Dec; 108(6):1274-1288. PubMed ID: 32564368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Efficacy and Safety of PD-1/PD-L1 Inhibitors in Combination with Conventional Therapies for Advanced Solid Tumors: A Meta-Analysis.
    Nie RC; Zhao CB; Xia XW; Luo YS; Wu T; Zhou ZW; Yuan SQ; Wang Y; Li YF
    Biomed Res Int; 2020; 2020():5059079. PubMed ID: 32461994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects and safety of PD-1/PD-L1 inhibitors on head and neck cancer: A systematic review and meta-analysis.
    Wang BC; Cao RB; Li PD; Fu C
    Cancer Med; 2019 Oct; 8(13):5969-5978. PubMed ID: 31436392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative efficacy and safety of PD-1/PD-L1 Inhibitors versus platinum-based chemotherapy for the first-line treatment of advanced non-small cell lung cancer: a meta analysis of randomized controlled trials.
    Li ZQ; Yan HC; Gu JJ; Yang YL; Zhang MK; Fang XJ
    Pharmacol Res; 2020 Oct; 160():105194. PubMed ID: 32937178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of combination PD-1/PD-L1 checkpoint inhibitors for malignant solid tumours: A systematic review.
    Yao Q; Gu L; Su R; Chen B; Cao H
    J Cell Mol Med; 2020 Nov; 24(22):13494-13506. PubMed ID: 33078904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-1 inhibitors monotherapy in hepatocellular carcinoma: Meta-analysis and systematic review.
    Voutsadakis IA
    Hepatobiliary Pancreat Dis Int; 2019 Dec; 18(6):505-510. PubMed ID: 31551142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.